Back to search results

Genetic Testing Uptake Study for Solid Tumors

This study is looking at ways to help more adult cancer patients with solid tumors get genetic counseling and testing (GCT). GCT can help understand your cancer risk and guide treatment for you and your family. The study will compare two approaches: one where nurses provide extra education about GCT and help with referrals, and another where patients receive standard information. Researchers want to see if the enhanced nurse-led education helps more patients go for GCT consultations. You may be eligible if you are an adult with certain solid tumor cancers like breast, ovarian, or prostate cancer. The study aims to enroll 60 participants.

Study design
This interventional study plans to enroll 60 adult participants with solid tumors. It compares two different educational approaches for genetic testing.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed to see if they proceed to GCT consultation, with measurements taken through study completion, an average of 9 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06436157

A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention

Recruiting
NAAges 18+InterventionalSupportive care
University of California, Davis
~60 participants
Updated 2025-01-31 on ClinicalTrials.gov
What's tested:Enhanced educationUsual care education

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of patients in each arm who proceed to GCT consultation following the intervention.
Measured over Through study completion, an average of 9 months

Conditions

Solid Tumor, Adult

Explore related trials

Solid Neoplasm

NCT06436157

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Enloe Regional Cancer Center

    Chico, Californiastudy coordinator listed

    Recruiting

  • University of California, Davis

    Sacramento, Californiano site contact published

    Active, not recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ranjan Pathak, MD MHS · PRINCIPAL_INVESTIGATOR · Enloe Health

Who to contact

Rachel A Kitchen, CCRP
[email protected]
406-417-1576
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults (≥ 18 years)
Diagnosed with a solid tumor cancer type that has established guidelines suggesting the utility of genetic testing in treatment (breast, ovarian, prostate, pancreatic, colon, Lynch syndrome-related cancers (colorectal, endometrial, gastric, ovarian, pancreatic, urothelial, brain (usually glioblastoma), biliary tract, small intestine), Li-Fraumeni syndrome tumor spectrum (e.g., soft tissue sarcoma, osteosarcoma, central nervous system tumors, breast cancer, adrenocortical carcinoma), etc.)
Eligible for GCT based on the current NCCN guidelines
Starting new systemic therapy or switching systemic therapy
Eligible for GCT as per the current NCCN guidelines
No prior genetic testing (or tested before 2014)

Exclusion

Prior GCT with test results available (if tested 2014 onwards)
Patients scheduled for treatment education with Advanced Practice Provider (typically reserved for more complex regimens)
Patients with cognitive impairments or severe psychological disorders that would limit their ability to understand the genetic counseling/testing information or give informed consent.
Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures (e.g., patients requiring urgent therapy and/or inpatient chemotherapy initiation).
Patients who are currently participating in other clinical trials that could confound the outcomes of genetic testing uptake.
Prospective participants who, in the investigator's opinion, may not be able to comply with all study procedures (including compliance issues related to logistics).
Hematologic malignancy

What this trial measures

  • Percentage of patients in each arm who proceed to GCT consultation following the intervention.Through study completion, an average of 9 months